Neumora Reports Favorable Toxicology for NMRA-215, Plans Phase 1 by Year-End
NMRA sits 83% above its 52-week low of $0.83 on light trading volume (0.3× avg).
Summary
Neumora reported favorable repeat toxicology results for NMRA-215, a NLRP3 inhibitor for obesity, and plans to submit an IND in Q4 2026 and start a Phase 1 trial by year-end. This is a key pipeline milestone after the recent discontinuation of its lead depression drug.
Key Events · Product Development and Regulatory · NMRA
-
Favorable Toxicology for NMRA-215
A repeat 13-week rat toxicology study showed no unexpected adverse findings, resolving a prior safety signal. The company believes the earlier findings were not drug-related.
-
IND Submission Planned Q4 2026
Neumora plans to submit an Investigational New Drug application in Q4 2026 and initiate a Phase 1 clinical study by the end of 2026.
-
Pipeline Rebuilding After Setback
This news comes six weeks after the company discontinued its lead depression drug navacaprant and cut 35% of its workforce. NMRA-215 is now the lead wholly-owned program.
-
Preclinical Efficacy Data Highlighted
NMRA-215 showed class-leading weight loss as monotherapy and additive effects with semaglutide in a diet-induced obesity mouse model, along with improved cardiometabolic biomarkers.
Analysis · NMRA · Life Sciences
Neumora announced favorable repeat toxicology results for NMRA-215, its NLRP3 inhibitor for obesity, clearing a prior safety concern. The company plans to submit an IND in Q4 2026 and start a Phase 1 trial by year-end. This is a critical pipeline advancement for a company that recently discontinued its lead depression drug and cut 35% of its workforce. NMRA-215 now becomes the most advanced wholly-owned asset, and positive preclinical data helps rebuild confidence after the June 2026 setback. The stock trades at $1.52, reflecting deep skepticism; this news could shift the narrative if the program progresses.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NMRA was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276.1M. The 52-week trading range was $0.83 to $3.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.